Louisiana coronavirus: 503 more cases, 10 more deaths reported Wednesday; see latest data | Coronavirus

The Louisiana Department of Health reported 503 more coronavirus cases and 10 more deaths in its noon update Wednesday.

The number of hospitalizations increased by 13, and the number of patients in need of ventilators decreased by 11.

These are another few key statewide statistics as of Wednesday:

— Total cases: 181,443

— Total deaths: 5,676

— Currently hospitalized: 613

— Currently on ventilators: 80

— Presumed recovered: 168,634 as of Oct. 26 (updated weekly)

— Probable cases: 4,379 as of Oct. 28 (updated weekly)

Note: The Advocate and The Times-Picayune staff calculates daily case count increases based on the difference between today’s total and yesterday’s total of confirmed coronavirus cases. The Louisiana Department of Health releases a daily case count on Twitter based on the deletion of duplicate cases. That case count can be different than the one listed here.

You can view more graphs and charts breaking down the data by clicking here.

Louisiana began reopening for Phase 1 on May 15-16 then moved to Phase 2 on June 5. Louisiana Gov. John Bel Edwards extended Louisiana’s Phase 2 restrictions twice in August before moving the state to Phase 3 on Sept. 11.

This is a developing story. More details and analysis to come.

Source Article

Read more

Highly anticipated COVID-19 vaccine data from Pfizer unlikely to come before Election Day: CEO

ABC News Corona Virus Health and Science

“This will not be a Democratic vaccine or Republican vaccine.”

Pfizer executives said in a third-quarter investor presentation on Tuesday they have not seen the first interim efficacy data yet. The Data Monitoring Committee, an independent group of experts monitoring the clinical studies and the data collection, “has not conducted any interim efficacy analyses to date,” according to Pfizer.

The slight delay from an earlier prediction of data by the end of October means results will likely not be known by Election Day, despite claims by President Donald Trump for months that a vaccine is “weeks away.”

The Data Monitoring Committee has thresholds for review that are triggered when a certain number of trial volunteers become sick with COVID-19. The first interim analysis is scheduled to happen when 32 people develop COVID-19, according to Pfizer’s extensive clinical trial protocol.

Bourla said, however, the company is still on track for a November application for authorization, if the vaccine shows to be effective and, just as importantly, safe.

Pfizer CEO Albert Bourla had previously said the company “may know whether or not our vaccine is effective by the end of October.”

Once there are 32 volunteers infected with COVID-19, Pfizer will analyze how many of them received the vaccine and how many received a placebo. If more than 76.9% of the grouping is in the placebo group, Pfizer will consider the vaccine efficacious.

Once an independent review board releases information on the trials, the company will need a week to review it internally, Bourla said.

Pfizer plans to release the interim data if it is negative (worse than 11.8%) or positive (better than 76.9%) for efficacy. If the data is somewhere in between, Pfizer will wait for more conclusive results, Bourla said.

“In case of a conclusive readout, positive or negative, we will inform the public as soon as we complete the necessary administrative work, which we estimate to be completed within one week from the time we know,” he explained to investors, adding that the company “reached the last mile here and we expect these things will start coming soon, so let’s all have patience.”

He said he is “cautiously optimistic” the vaccine will work based on earlier studies.

PHOTO: Medical syringes stand in front of the Pfizer company logo, Oct. 12, 2020.

Medical syringes stand in front of the Pfizer company logo, Oct. 12, 2020.

Pfizer said it expects efficacy and safety data will be available in November, and if it is, it will apply for emergency use authorization.

Pfizer’s vaccine candidate was also developed with the German biotech firm BioNTech. There are 150 clinical trial sites around the world.

More than 42,000 participants have been enrolled and nearly 36,000 have received a second dose of the vaccine. Expanding the number of participants has allowed trials to include additional populations, among them children between 12 and 18 and people with preexisting conditions.


Read more

Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?

When it comes to winning biotech stocks this year, coronavirus vaccine developers automatically come to many investors’ minds. However, one of the top-performing stocks in the sector is Northwest Biotherapeutics (OTC:NWBO), which focuses on immunotherapies that treat cancer, and has returned a staggering 408% since January.

The main reason why investors are so excited about Northwest Biotherapeutics’ prospects is that the company’s 14-year-long phase 3 clinical trial to evaluate its one and only immunotherapy candidate, DCVax-L, as a treatment for glioblastoma, has concluded. Should you consider buying the stock in anticipation of the data release? Let’s find out together. 

3-D illustration of a dendritic cell.

Image source: Getty Images.

Treatment background

Glioblastoma is a deadly form of brain cancer prevalent in up to 15% of people with brain tumors. Even after patients receive standard of care (SOC) treatments consisting of surgery, chemotherapy, and radiotherapy, their median survival time comes down to just 15.5 months in historical studies. DCVax-L is an experimental immunotherapy that seeks to stimulate patients’ own immune systems to fight cancer growth. 

The potential biologic has been in phase 3 clinical trials since December 2006. In the study, all glioblastoma patients receive SOC treatments, while a random portion also receives DCVax-L via upper arm injections. A key trial endpoint requires at least 233 patient deaths out of a total of 331 participants enrolled to calculate a survival benefit for DCVax-L, if any. The company completed its study on July 24, and the data is currently being reviewed by statisticians. In the meantime, speculations on the results have ranged from wildly enthusiastic to pessimistic from excited investors and short-sellers. 

The bullish case

The bullish case for Northwest Biotherapeutics stock is straightforward: The DCVax-L clinical trial was supposed to wrap up as early as November 2016, but had to keep going because the projected number of deaths had not occurred by then.

Around the time when the trial was enrolling, only 3% of glioblastoma patients who received SOC survived over five years. Due to extremely low survival rates for patients who receive SOC treatments, bullish investors argue that there is no other logical explanation for the clinical study going into overtime than DCVax-L keeping patients alive longer than expected. 

The bearish case

The bearish case is a lot more complicated.

Clinical trials investigating experimental biologics for deadly diseases with a lack of therapeutic options usually have pre-planned interim analyses. DCVax-L’s phase 3 trial had two such analyses built into the study.

The analysis is conducted by an independent data-monitoring committee (DMC) that can recommend that the trial stop early if an experimental therapy demonstrates statistically meaningful efficacy against SOC treatments. This way, the biologic can quickly advance to the approval stage in order to save more lives.

Northwest Biotherapeutics’ DMC carried out two interim analyses on the DCVax-L study in 2017 and 2018 (more on this later). Both times, however, the company published the DMC’s findings as blinded, and the trial continued. Unfortunately, that doesn’t make any sense at all in the context of

Read more

Pfizer says no COVID-19 vaccine data yet, could be week or more before it reports

By Michael Erman and Manas Mishra

(Reuters) – Drugmaker Pfizer Inc <PFE.N> said on Tuesday it does not yet have data from the late-stage trial of the COVID-19 vaccine it is developing with Germany’s BioNTech SE <22UAy.F>, and provided a timeline that makes its release unlikely ahead of the Nov. 3 U.S. presidential election.Pfizer said there had not yet been enough infections in the 44,000-volunteer trial to trigger an analysis of whether or not the vaccine works. An independent panel will conduct the first analysis when it reaches 32 infections.

Chief Executive Albert Bourla said after it has enough data for the analysis, it typically takes 5 to 7 days before the company can publicly release the data, meaning it is likely to happen after the election.

U.S. President Donald Trump had said a vaccine could be available before the Nov. 3 election, but in recent weeks his administration has emphasized that one will be ready this year.

Bourla has previously said the company could release data on whether or not the vaccine works as early as this month.

“For us, the election is an artificial milestone,” Bourla said on a conference call for the company’s earnings. “This is going to be not a Republican vaccine or a Democrat vaccine. It will be a vaccine for the citizens of the world.”

Pfizer shares were flat at $37.92.

Pfizer hopes to be the first U.S. drugmaker to unveil successful data from a late-stage COVID-19 vaccine trial, ahead of rival Moderna Inc <MRNA.O>. Pfizer and BioNTech launched their phase 3 study in late July.

The data monitoring board is scheduled to make its first assessment of the vaccine’s performance after 32 participants in the trial become infected with the novel coronavirus.

Healthcare investor Brad Loncar said it was difficult to draw a positive or negative conclusion from the fact that the trial has not yet had its first interim analysis.

“I think this means that the overall infection rate is a lot lower than Pfizer initially estimated,” Loncar said.

Dr. David Boulware, professor of medicine at University of Minnesota, said the study’s participants may be more adherent to social distancing guidelines than the general population.

“Who the vaccine trials really need are the people who don’t wear masks, who are going out to bars, who go to crowded events, who are singing in church choirs – those are the high risk people,” he said.

Boulware said that a data monitoring board could still review the data relatively quickly – perhaps in less than a day – once the trial hits its first interim point.

As the pandemic crimps demand for certain Pfizer therapies and damages global economies, investors are keenly focused on seeing the late-stage study data of the vaccine candidate being developed with BioNTech.

The company also said that if the trial is successful, it still expects to file for emergency authorization of the vaccine candidate from U.S. regulators shortly after it has enough safety data in late November.

Read more

New Hampshire COVID-19 Positivity Test Rate At 1.6%: Data

CONCORD, NH — Two more elderly men have died due to or from COVID-19, according to New Hampshire health officials.

The men both lived in long-term care settings in Hillsborough County and were 80 years of age or older. The State Joint Information Center offered sympathies to family members and friends of the men. The state said 475 deaths are related to COVID-19 exposure.

Another 77 people in the Granite State tested positive for the coronavirus including eight children after more than 5,200 specimens were collected Sunday. Slightly more than half the cases were male. About 800 tests are pending for a polymerase chain reaction test positivity rate of 1.6 percent Monday. About two-thirds of the new positive test results were discovered by PCR rests.

The new positive test results bring the accumulative county to 10.397 with 8,920 or about 86 percent recovered.

Most of the new cases were from Rockingham County — 18, while 15 live in Merrimack County, 10 reside in Hillsborough County outside of Manchester and Nashua, and seven live in Nashua.

Twenty-five people are currently hospitalized with COVID-19 and 1,002 people are current cases.

The state said Monday that 333,115 people have been tested via PCR tests and 32,015 have been tested by antibody lab tests. More than 585,000 PCR tests have been administered in New Hampshire.

About 4,450 residents are under public health monitoring.

Editor’s note: Due to technical problems with the state’s COVID-19 charts, more data and information was not available at post time.


Stop The Spread Of COVID-19

The COVID-19 virus is spread through respiratory droplets, usually through coughing and sneezing, and exposure to others who are sick or might be showing symptoms.

Health officials emphasize residents should follow these recommendations:

  • Avoid any domestic and international travel, especially on public transportation such as buses, trains, and airplanes.

  • Practice social distancing. Stay at least 6 feet from other people, including distancing while in waiting areas or lines.

  • When you can’t practice 6 feet of social distancing, wear a face covering.

  • Anyone who is told to self-quarantine and stay at home due to exposure to a person with confirmed or suspected case of COVID-19 needs to stay home and not go out into public places.

  • If you are 60 years or older or have chronic and underlying health conditions, you need to stay home and not go out.

  • Avoid gatherings of 10 people or more.

  • Employers should work from home as much as possible.

  • There is increasing evidence that the virus can survive for hours or possibly days on surfaces. People should clean frequently touched surfaces, including door handles, grocery carts and grocery basket handles, etc.

Take the same precautions as you would if you were sick:

  • Stay home and avoid public places.

  • Wear a face covering.

  • Cover mouth and nose when coughing and sneezing.

  • Wash hands frequently.

  • Disinfect frequently touched surfaces.

More information from the New Hampshire Department of Health and Human Services about coronavirus can be found here on

Read more

More Data Tie Biologics to Fewer Colectomies in Ulcerative Colitis

Trends in colectomy rates over the past 2 decades reinforced data that biologics may reduce the need for colectomy in ulcerative colitis (UC), a researcher reported here.

A temporal trends analysis found the prevalence of colectomy decreased from 10.8% in 2000 to 2.1% in 2019, and this decline coincided with a linear increase in the prevalence of biologic medication utilization in UC from 0.5% in 2000 to 12.8% in 2019 (P<0.001), according to George Khoudari, MD, of the Cleveland Clinic and Case Western Reserve University.

“Although prior smaller data sets have suggested a decrease, there were no population-based studies to evaluate biologics on colectomy,” senior author Miguel Regueiro, MD, also of the Cleveland Clinic,” said in an interview. “We felt that evaluation of a real world large population-based database would be important.”

Data were extracted from the commercial database Explorys, a repository of electronic health records data from 26 major integrated U.S. healthcare systems from, he explained in a presentation at the American College of Gastroenterology virtual meeting.

Using Systematized Nomenclature of Medicine Clinical Terms, the investigators identified all UC patients older than age 18 to examine the prevalence of UC-related colectomy and biologics utilization. Biologics included anti-tumor necrosis factor, anti-integrin, and anti-interleukin-12/23 agents.

Of 61,592,650 patients in the database, 46,430 were diagnosed with UC from 2000 to 2019. Of these, 15,020 (10.2%) had colectomy and 10,050 (6.8%) were treated with biologics. After adjusting for other therapies such as mesalamine, corticosteroids, and thiopurines, biologics were inversely related to colectomy (P<0.001, respectively, while there was no inverse relationship between mesalamine and colectomy (P<0.001).

According to Regueiro, current data support the effectiveness of earlier use of biologics in the disease course. “Earlier use allows for better rates of healing and less inflammation equates to less likely need for colectomy.” But is it possible that biologics just delay the need for colectomy, especially in severe cases? “For patients hospitalized, which is not the population we studied, yes this is possible,” he said. “However there is some information coming out soon that complete remission of severe cases would also lead to less surgery, not just in the short term but the long term.”

Edward L. Barnes, MD, of the University of North Carolina at Chapel Hill, commented that the study was “an important next step in demonstrating what now appears to be a strong signal of a decreasing colectomy rate in recent years with the increased prevalence of biologic use among UC patients.”

While gastroenterologists have been optimistic that biologics would reduce colectomies, “this was initially only a hope,” said Barnes, who was not involved with the research. The current study as well as others support a genuine effect on colectomy rates.

And given that the new analysis included some of the newest UC treatments, such as anti-integrin and anti-interleukin-12/23 therapies, “there is hope that, with continued advancement of our therapeutic armamentarium, we will see a progression of this trend,” he said.

But Barnes added, “It is important

Read more

Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate Cancer

Data presented by City of Hope at 27th Annual Prostate Cancer Foundation Scientific Retreat

WORCESTER, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that one patient‘s experience on the Phase 1 trial of MB-105, a prostate stem cell antigen (PSCA) chimeric antigen receptor (CAR) T administered systemically to patients with PSCA-positive metastatic castration-resistant prostate cancer (mCRPC), was presented at the virtual 27th Annual Prostate Cancer Foundation Scientific Retreat.

Tanya Dorff, M.D., City of Hope Associate Clinical Professor, Department of Medical Oncology & Experimental Therapeutics and Head of its Genitourinary Cancer Program and the trial’s principal investigator, presented a description of the correlative science from the ongoing Phase 1 open-label clinical trial of MB-105, one of the first CAR T trials for prostate cancer in the nation. In a 73-year-old male patient with PSCA-positive mCRPC who was treated with MB-105 and lymphodepletion (a standard CAR T pre-conditioning regimen) after failing eight prior therapies, MB-105 demonstrated on day 28 a 94 percent reduction in prostate-specific antigen (PSA), near complete reduction of measurable soft tissue metastasis by computerized tomography, and improvement in bone metastases by magnetic resonance imaging. The therapy was associated with cytokine release syndrome, which was clinically managed with tocilizumab (anti-IL-6 receptor antibody), and hemorrhagic cystitis requiring transfusion which clinically resolved in 30 days.

Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “We are encouraged by the initial data presented by City of Hope from the ongoing Phase 1 trial of Mustang’s CAR T cell therapy MB-105. We see potential for this PSCA-targeted CAR T in the treatment of prostate cancer, as well as other difficult-to-treat solid tumor cancers. We look forward to the continued progression of this trial and anticipate providing further data in the second half of 2021.”

According to the American Cancer Society (ACS), prostate cancer is the most common cancer in American men, excluding skin cancer. ACS estimates 191,930 new cases of prostate cancer in the U.S. will be diagnosed this year, and roughly one out of every nine men will be diagnosed with prostate cancer during his lifetime. The median survival for men with CRPC is less than two years, according to the American Urological Association.

About MB-105 (PSCA CAR T technology)
MB-105 was developed in the laboratory of Saul Priceman, Ph.D., assistant professor in City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation and associate director of translational sciences in the T Cell Therapeutics Research Laboratory led by Stephen Forman, M.D., leader of City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute and the laboratory’s director.

The Phase 1 clinical trial of MB-105 will continue to enroll up to 33 patients. Its primary endpoints are to define safety and optimal dosing of PSCA CAR T cells in treating patients with PSCA-positive mCRPC. Secondary

Read more

Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020

Basel, Switzerland, October 26, 2020

Basilea Pharmaceutica Ltd. (SIX: BSLN) today reported that data on the anti-angiogenic activity of the fibroblast growth factor receptor (FGFR) inhibitor derazantinib were presented at the 32nd EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, that took place as a virtual event on 24-25 October, 2020. In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2). The presented data from several preclinical models demonstrate that derazantinib has an anti-angiogenic effect, which may contribute to its overall anti-tumor activity in FGFR-driven cancers.

The prevention of new blood vessel formation (anti-angiogenesis) is an established approach in cancer therapy as it deprives the growing tumor from oxygen and nutrients. VEGFR2 is a primary target for anti-angiogenic agents in the treatment of cancers.

Dr. Laurenz Kellenberger, Chief Scientific Officer, said: “Our development strategy for derazantinib is focused on strengthening the evidence for its differentiation versus other FGFR inhibitors. The preclinical data on derazantinib’s anti-angiogenic activity presented at the conference show that it may provide additional activity on top of its established primary anti-tumor effects in FGFR-positive solid tumors. Based on its unique kinase inhibition profile, we are exploring derazantinib’s potential for enhanced activity alone and in combination with other anti-cancer agents such as the anti-VEGFR2 antibody ramucirumab, or the PD-L1 immune checkpoint inhibitor atezolizumab within our ongoing clinical program FIDES.“

The following e-poster was presented at the EORTC-NCI-AACR Virtual Symposium 2020:

Presentation #



P. McSheehy, J. Boult, S. Robinson, F. Bachmann, M. El-Shemerly, L. Kellenberger, H. Lane

Derazantinib, an oral fibroblast growth factor receptor inhibitor, in phase-2 clinical development, shows anti-angiogenic activity in preclinical models

For further information, please visit https://event.eortc.org/ena2020

About derazantinib

Derazantinib is an investigational orally administered small-molecule FGFR inhibitor with strong activity against FGFR1, 2, and 3.1 FGFR kinases are key drivers of cell proliferation, differentiation and migration. FGFR genetic aberrations, e.g. gene fusions, mutations or amplifications, have been identified as potentially important therapeutic targets for various cancers, including intrahepatic cholangiocarcinoma (iCCA), urothelial, breast, gastric and lung cancers.2 In these cancers, FGFR genetic aberrations are found in a range of 5% to 30%.3
Derazantinib also inhibits the colony-stimulating-factor-1-receptor (CSF1R) kinase.1, 4 CSF1R-mediated signaling is important for the maintenance of tumor-promoting macrophages and therefore has been identified as a potential target for anti-cancer drugs.5 Preclinical data has shown that tumor macrophage depletion through CSF1R blockade renders tumors more responsive to T-cell checkpoint immunotherapy, including approaches targeting PD-1/PD-L1.67
Derazantinib has demonstrated antitumor activity and a manageable safety profile in a previous biomarker-driven phase 1/2 study in iCCA patients,8 and has received U.S. and EU orphan drug designation for iCCA. Basilea is currently conducting three clinical studies with derazantinib. The first study, FIDES-01, is a registrational phase 2 study in patients with inoperable or advanced iCCA. It comprises one cohort of patients with FGFR2 gene fusions and another cohort of patients with mutations or amplifications.

Read more

Active COVID-19 Cases In New Hampshire The Most Since June: Data

CONCORD, NH — Another 92 New Hampshire residents tested positive for COVID-19 after more than 7,000 polymerase chain reaction specimens were collected on Saturday.

Prior test counts were upgraded and nearly 900 tests are pending bringing the daily positivity rate to 0.8 percent. Most of the positive tests were found via PCR testing with a little less than a third by antigen tests.

There are currently 1,032 active COVID-19 cases diagnosed in New Hampshire — the most since mid-June.

Hospitalizations in New Hampshire are still low — 23 and only 7 percent of cases required more care since the pandemic started in early March.

Of the new cases, 12 were children, cases were split nearly evenly between women and men, and some cases are still under investigation by the state, including determining the residency of five new cases. Of the rest, 23 reside in Rockingham County, 20 live in Hillsborough County outside of Manchester and Nashua, 10 live in Merrimack, and nine live in Nashua. The increase in cases today as well as extensive numbers during the past few weeks in Rockingham County, including outbreaks at Portsmouth restaurants, have pushed the county into the substantial community transmission category on the school data dashboard.

“Five of the new cases had no identified risk factors,” the State Joint Information Center said. “Community-based transmission continues to occur in the State and has been identified in all counties. Of those with complete risk information, most of the cases have either had close contact with a person with a confirmed COVID-19 diagnosis, are associated with an outbreak setting, or have recently traveled.”

Accumulatively, 10,328 have been diagnosed with coronavirus while 8,823 have recovered from the virus — about 85 percent. The state said 331,561 residents have been tested or 22.2 percent via 579,186 PCR tests. Another 32,000 people have been tested with antibody tests.

Approximately 4,450 people are under public health monitoring in New Hampshire.

In K-12 schools in New Hampshire, there are 66 active cases after the state reported a number of new school cases since Friday.

Heron Pond Elementary School in Milford has two active cases; Manchester Central High School has its first case; Milford High School has two new active cases; North Hampton School has a second new active case; the Penacook Elementary School in Concord has a new case; the Riddle Brook Elementary School has its four active case; the South Range Elementary School in Derry has its second active case; and Saint Joseph Regional School in Keene and St. Mary Academy in Dover both have their first cases.

There are also five active cases at the University of New Hampshire School of Law in Concord while there are 18 active cases at UNH in Durham. The university has 187 cases. Plymouth State College and Keene State College have four active cases each while Colby-Sawyer College, Dartmouth College, Franklin Pierce University, and White Mountains Community College have a single case each. Rivier University has five active cases while New England College

Read more

Alabama adds 3,852 COVID cases after influx of backlogged data dating back to June

Alabama added more than 3,800 COVID cases yesterday after a huge influx of backlogged data dating back to June.

The Alabama Department of Public Health showed a total of 180,916 coronavirus cases in the state, up 3,852 from the day before. Of that total, 973 were confirmed cases and 2,879 were probable. Of that 2,879, the 2,565 were antigen tests from a facility in Mobile that dated back to the summer.

The cases “will be classified as probable COVID-19 cases reported on 10/22/20 even though the tests were performed during June through Oct. 18. All laboratories are required by law to report all results (including positive and negative results) for (COVID-19) to ADPH,” the agency said in an announcement.

“Delays in reporting by required reporters is not within control of ADPH. Processing the backlog will not impact the ADPH COVID-19 Risk Indicator Dashboard,” ADPH added.

The state added 16 deaths to bring its total to 2,859.

ADPH reports 864 patients are currently hospitalized due to coronavirus.

Here are the latest county-by-county numbers from the Alabama Department of Public Health. The numbers include both confirmed and probable cases with the overnight increases shown in parenthesis:

Autauga – 2030 (+7)

Baldwin – 6615 (+140)

Barbour – 1012 (+15)

Bibb – 825 (+14)

Blount – 1911 (+13)

Bullock – 639 (+2)

Butler – 1002 (+1)

Calhoun – 4224 (+35)

Chambers – 1343 (+7)

Cherokee – 731 (+5)

Chilton – 1858 (+17)

Choctaw – 390 (+2)

Clarke – 1336 (+36)

Clay – 736 (+7)

Cleburne – 551 (+8)

Coffee – 1732 (+15)

Colbert – 1987 (+20)

Conecuh – 560 (+3)

Coosa – 203 (+1)

Covington – 1714 (+15)

Crenshaw – 603 (+1)

Cullman – 2399 (+42)

Dale – 1665 (+11)

Dallas – 1863 (+1)

DeKalb – 3360 (+58)

Elmore – 3173 (+24)

Escambia – 1722 (+3)

Etowah – 4214 (+27)

Fayette – 569 (+8)

Franklin – 2032 (+11)

Geneva – 861 (+9)

Greene – 342

Hale – 758 (+9)

Henry – 643 (+4)

Houston – 3717 (+25)

Jackson – 2125 (+25)

Jefferson – 22987 (+137)

Lamar – 474 (+8)

Lauderdale – 2180 (+32)

Lawrence – 837 (+16)

Lee – 6517 (+21)

Limestone – 2797 (+32)

Lowndes – 704 (+1)

Macon – 530 (+1)

Madison – 9228 (+78)

Marengo – 1002 (+10)

Marion – 1071 (+9)

Marshall – 4372 (+42)

Mobile – 16,788 (+2,320)

Monroe – 645 (+5)

Montgomery – 9978 (+103)

Morgan – 4071 (+35)

Perry – 585 (+2)

Pickens – 836 (+12)

Pike – 1327 (+4)

Randolph – 820 (+8)

Russell – 1928 (+5)

St. Clair – 2891 (+20)

Shelby – 7274 (+70)

Sumter – 472 (+2)

Talladega – 2636 (+25)

Tallapoosa – 1313 (+8)

Tuscaloosa – 10,235 (+87)

Walker – 2755 (+33)

Washington – 734 (+100)

Wilcox – 564 (+2)

Winston – 919 (+6)

Source Article

Read more